Nuklearmedizin und Strahlentherapie

"Complementary Contribution of Positron Emission Tomography "PET" and MRI in the Management Of Prostate Cancer in Initial Extension Assessment and in Biological Relapse"

Abstract

Alshemeili. Manea, Philippe. Got

Introduction: Prostate cancer is currently the second leading cause of cancer death in men in Europe and developed countries, with about 300,000 new cases diagnosed each year. The respective roles of multipara metric MRI and nuclear medicine by PET with choline or other tracers for prostate cancer (CaP) exploration have expanded in recent years thanks to technical advances and the development of functional imaging.

Methods: From October 2017 to December 2018, 20 patients were included retrospectively to search local localization of prostate cancer with or without nodal and bone metastasis. The indication was 8/20 for initial assessment and 12/20 for biologic recurrence after prostatectomy or radiotherapy. all benefited a multi parametric pelvic MRI (T2, diffusion, dynamic after injection) and a choline PET at the nuclear medicine department, XXX center using PET-CT (GE Discovery 710).

Results: Patients had 80% of identical results in PET scan and MRI, while 10% had a negative result in MRI and positive in PET-scan and 10% had a positive result in MRI and negative in PET-scan.

Conclusion: The innovative imaging modalities available today, using advanced MRI and PET technologies and the appearance of new tracers more sensitive and specific than choline can improve the diagnostic performance and strategies of treatment planning.